Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

ABSTRACT:

SUBMITTER: Ravandi F 

PROVIDER: S-EPMC6278965 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature